Kidney Cancer Disease Study CRAD001L2201 Clinical Trial Information

Novartis Clinical Trials and Medical Research Studies Recruiting in the U.S.

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Novartis Clinical Trials provides information about research studies recruiting within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S.

Study Description

Screening

Study Centers

Contact/Consent

Kidney Cancer Disease Study CRAD001L2201

The purpose of this medical research is to study the effects of combining a Novartis investigational drug with an existing therapy, when treating people with metastatic clear cell carcinoma of the kidney (Kidney Cancer). An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 2
Participation Duration: Participants will be required to visit their study site every two weeks for approximately two years. One group will be required to inject themselves three times a week and return to the study site every two weeks for an additional infusion treatment. Another group, will be required to take two tablets every day and return to the site every two weeks for an additional infusion treatment.
Protocol Number: CRAD001L2201

The next step is to see if you (or the participant) meet the basic criteria required for participation in this clinical trial. Please fill out the questionnaire below to see if you (or the participant) may be suitable for the clinical trial. Your answers to these questions are not retained by this system. You must answer the questions below for yourself, or, you must be the legally authorized representative of the potential participant in order to answer the questions on their behalf. If you (or the participant) do not meet the preliminary qualifications, you may search for other clinical trials of interest or sign up to the Mailing List.

Answers to all questions are required to determine if you meet the preliminary qualifications for the study.

1) Participation in a clinical trial will require travel to a study center where the clinical trial is being conducted. How far would you (or the participant) be willing to travel to a study center to participate in this clinical trial? Please note that participation in these clinical trials may require a number of visits to the study center and travel expenses may not be covered.

25 miles 50 miles 100 miles 150 miles Unlimited

2) Please enter your residential postal zip code.

3) Are you 18 years or older?
Yes
No

4) Do you have a doctor’s diagnosis of progressive metastatic renal cell carcinoma of the kidney (Kidney Cancer) that requires treatment?
Yes
No

5) Have you received prior treatment for renal cell carcinoma (not including added immunotherapy completed within the past three months)?
Yes
No

6) Have you had a history of heart disease or stroke within the past 6 months?
Yes
No

7) Do you have a history of lung disease, liver disease, hepatitis, diabetes, HIV disease, gastrointestinal surgery and/or inflammatory bowel disease?
Yes
No

8) Have you had a partial or complete nephrectomy?
Yes
No

9) Have you had a history of cancer (not Kidney Cancer or basel cell skin cancer or cervical cancer) within the past 3 years?
Yes
No

10) Do you have a history of hypertension or diabetes that is not currently controlled with standard medical treatment?
Yes
No

11) Do you have a history of seizures that are not controlled with standard medical therapy?
Yes
No

12) Are you currently pregnant or breastfeeding?
Yes
No

13) Are you currently receiving treatment with corticosteroids (not including inhaled or topical steroids)?
Yes
No

	Site Map \| Contact Us \| Find a Clinical Trial \| Mailing List \| Clinical Trial FAQs
	Clinical Trials Glossary \| About Informed Consent \| Medical Research Areas
	Clinical Trial Resources \| How to use this website